Cadila's renewed focus on India biz, Covid-19 opportunities lend confidence

Renewed focus on India, new drug launches in US lend comfort

Cadila Healthcare reported a subdued showing for the March 2020 quarter (Q4), partly on account of last year’s high base and the Covid-led supply disruptions.

Yet, investor confidence remains firm, reflected in its stock that continues to trade near 52-week highs. The key factor is the drug major’s strong outlook. 

Revenues in Q4 came in flat. While domestic sales — which contribute about a fourth to overall revenue — were also little changed, US sales (47 per cent of the top line) declined by 1.2 per cent year-on-year (YoY).

Sales in emerging markets and Latam were also weak, as supply